Moreover, patients with high YBX1 expression had a significantly shorter overall survival time; however, LC3I/II expression had no effect on overall survival time, suggesting that YBX1 could potentially serve as a diagnostic marker and an independent prognostic predictor for NSCLC progression. The gene discussed is YBX1; the disease is non-small cell lung carcinoma.